Rituximab in CD20 positive multiple myeloma.
Moreau
P
P
Voillat
L
L
Benboukher
L
L
Mathiot
C
C
Dumontet
C
C
Robillard
N
N
Hérault
O
O
Garnache
F
F
Garand
R
R
Varoqueaux
N
N
Avet-Loiseau
H
H
Harousseau
J L
JL
Bataille
R
R
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use* / Q000633:toxicity; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD / Q000235:genetics; D018951:Antigens, CD20 / Q000235:genetics*; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D015972:Gene Expression Regulation, Neoplastic / Q000276:immunology; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology; D011446:Prospective Studies; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab